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Abstract
BACKGROUND: Despite the concern on the impact of coronavirus disease (COVID)-19 on tuberculosis (TB), there 
is a paucity of information from the developing countries inclusive of Nigeria.
CASE REPORT: Hence, we report two cases of Nigerian’ adults with coinfections of severe acute respiratory 
syndrome coronavirus 2 and Mycobacterium tuberculosis (MTB). The two cases were males and aged 30 and 
33 years, respectively. They presented with cough, fever, and weight loss with features of acute respiratory 
symptoms and a history of contact with a confirmed COVID-19. The GeneXpert for MTB detected was high, and 
chest radiographs showed both features suggestive of TB, and COVID-19. They both received quadruple anti-TB 
regimen, along with lopinavir/ritonavir. The first case was discharged after 15 days, while the second patient died 6 
days into the admission.
CONCLUSION: This case reports showed that COVID-19 superimposed on TB may not be uncommon in our 
environment and may have a poorer outcome. Hence, there is a need for a high index of suspicion for TB infection 
in endemic area during the COVID-19 pandemic.
Edited by: Mirko Spiroski
Citation: Tekobo AG, Taofeek O, Olayinka RI , Abdallah S, 
Bello MS. Pulmonary Tuberculosis in Coronavirus 
Disease-19 Patients: A Report of Two Cases from Nigeria. 
Open Access Maced J Med Sci. 2020 Oct 19; 8(T1):272-275. 
https://doi.org/10.3889/oamjms.2020. 5298
Keywords: Coronavirus Disease-19; Pulmonary 
tuberculosis; Clinical features; Laboratory findings; 
Treatment; Nigeria
*Correspondence: Tekobo Abiodun Gbenga, 
Department of Internal Medicine, Federal Medical 
Centre, Katsina, Nigeria. Phone: +234-806-6499-807. 
E-mail: abteko@yahoo.com 
Received: 22-Jul-2020
Revised: 06-Oct-2020
Accepted: 09-Oct-2020
Copyright: © 2020 Tekobo Abiodun Gbenga, 
Taofeek Oloyede, Olayinka Rasheed Ibrahim, 
Abdallah Sanda, Bello Muhammed Suleiman
Funding: Publication of this article was financially 
supported by the Scientific Foundation SPIROSKI, Skopje, 
Republic of Macedonia
Competing Interests: The authors have declared that no 
competing interests
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
The global number of cases of coronavirus 
disease (COVID)-19 has risen above ten million with 
more than 500,000 deaths since the outbreak in 
December 2019 and the subsequent declaration as a 
global pandemic on the March 11, 2020 by the World 
Health Organization (WHO) [1], [2]. Nigeria is battling 
to curtail the disease with more than 25,000 cases and 
a case fatality rate of about 2.3% [3]. Besides, Nigeria 
has the seventh-largest tuberculosis (TB) burden in the 
world and the second highest-burden of TB in Africa [4]. 
With an estimated 407,000 cases of TB diagnosed 
annually in Nigeria, the potential impact of COVID-19 
may be more devastating [5], [6]. Available literature 
suggested that elderly and persons with comorbidities 
inclusive of chronic respiratory diseases such as TB 
are at higher risk of death than the general population 
from COVID-19 [7]. Patients with pulmonary TB (PTB) 
are known to have depressed cellular immunity and 
are thus susceptible to viral infections [8]. Despite the 
vulnerability of TB patients to viral infections, there are 
few reports and data on COVID-19 and TB since the 
outbreak of the pandemic [9]. Indeed, a recent review 
of 49 cases of coinfections of COVID-19 and TB had 
no data representation from Africa [10]. Besides, the 
common COVID-19 symptoms including cough, fever 
and shortness of breath overlap with symptoms of 
pulmonary tuberculosis which may make distinguishing 
between the two illnesses difficult for health care workers 
in high burden countries such as Nigeria. Therefore, we 
provide information on clinical presentation, laboratory 
findings, treatment, and outcome of two cases of 
confirmed COVID-19 infection with PTB managed at a 
treatment facility in Nigeria.
Case Reports
Case one
Patient one was a 33-year-old male adult who 
presented with a 2 months history of cough, productive 
scanty whitish sputum, low-grade fever, and weight 
loss. He had real-time reverse transcription-polymerase 
chain reaction (RT-PCR) for syndrome coronavirus 
2 (SARS-CoV-2) test using oropharyngeal and nasal 
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specimens due to a sore throat a week before the 
presentation and a history of contact with a confirmed 
case of COVID-19. The examination findings at admission 
revealed a young man, febrile with an axillary temperature 
of 37.8°C, mild pallor, and chest findings showed bilateral 
coarse crepitations with an oxygen saturation of 97% 
in room air (Table 1). The full blood count showed 
lymphopenia and anemia (Table 2), Sputum GeneXpert 
showed MTB detected high, HIV screening was negative, 
and liver function tests, electrolytes urea, and creatinine 
were within the normal limit (Table 2). Chest X-ray 
showed reticulonodular shadowing with peripherally 
based consolidation worse on the left, loss of volume on 
the left side with mediastinal shift to the left side, and early 
tenting of the right hemidiaphragm (Figure 1). He received 
antiviral (lopinavir/ritonavir), azithromycin, Vitamin C, Zinc 
sulfate, oral prednisolone, quadruple anti-TB agent, and 
tabs pyridoxine. We discharged home after 15 days on 
admission following the resolution of symptoms and two 
negative RT-PCR test for SARS-CoV-2 done 48 h apart.
Table 2: Laboratory findings of two adult patients diagnosed 
with COVID-19 and PTB
Variable Patient 1 Patient 2
FBC (×109/L) 6.2 13.1
Lymphocyte (%) 18.8 23.2
Neutrophils (%) 68.6 66.5
Monocytes (%) 14.9 10.0
Eosinophils (%) 6.3 0.2
Basophils (%) 0.3 0.1
PCV (%) 27.4 32.1
Platelets (×109/L) 236 72
EUCr
Na+ (mmol/l) 140 128
K+ (mmol/l) 4.3 4.3
Cl− (mmol/l) 99 99
HCO3− (mmol/l) 25 15
Urea (mmol/l) 3.1 2.9
Creatinine (Umol/l) 68 58
LFT
T/Protein 78 66
Albumin 28 34
ALP 100 100
ALT 21 19
AST 17 25
Total bilirubin 0.45 1.35
Direct bilirubin 0.07 0.1
RVS Negative Negative
Sputum GeneXpert MTB detected high MTB detected high
Chest radiograph Reticulonodular shadowing 
with peripherally based 
consolidation worse on the 
left side. Loss of volume on 
the left side
Extensive in homogenous opacity 
with some coalescing in both lung 
fields sparing the left apical and LLZ 
as well as the lower aspect of the 
right ULZ. There is air bronchogram 
seen within these opacities
PCV: Packed cell volume, ULZ: Upper lung zone, LLZ: Lower lung zone, FBC: Full blood count, 
RVS: Retroviral screening, EUCr: Electrolyte urea and creatinine, LFT: Liver function test, ALP: Alanine 
phosphatase, ALT: Alanine transaminase, AST: Aspartate transaminase, MTB: Mycobacterium tuberculosis. 
COVID: Coronavirus disease, TB: Tuberculosis, PTB: Pulmonary tuberculosis.
Case two
Patient two was a 30-year-old male who 
presented with a 6 months history of cough productive 
of scanty whitish and occasional brownish sputum (non-
frothy), no hemoptysis, low-grade fever, and weight loss. 
He developed difficulty in breathing 2 weeks before his 
admission, and a history of contact with a confirmed 
case of COVID-19 prompted the test for SARS-CoV-2 
using RT-PCR on oropharyngeal and nasal specimens 
which turned positive. The examination findings at 
presentation revealed a chronically ill-looking young 
man with an axillary temperature of 38.2°C, pallor, and 
ankle edema. He had a respiratory rate of 36 cpm with 
the right apical flattening and bronchial breath sound 
Table 1: Demographic and clinical presentation of two adult 
patients diagnosed with COVID-19 and PTB
Variable Patient 1 Patient 2
Age 33 years 30 years
Gender Male Male
Presenting 
complaints/
duration
Cough/2 months Cough/6 months
Fever/2 months Fever/2 months
Weight loss/2 months Weight loss/2 months
Sore throat/2 weeks Shortness of breath/2 weeks
Examination 
findings
Febrile(37.8°C) Febrile(38.2°C)
Pallor Pallor
Bilateral coarse crepitations Ankle edema
Oxygen saturation – 97% on RA Tachypnea
Right apical flattening and BBS 
on the right LLZ
Oxygen saturation – 89% in RA
RA: Room air, BBS: Bronchial breath sound, LLZ: Lower lung zone. COVID: Coronavirus disease, 
TB: Tuberculosis, PTB: Pulmonary tuberculosis.
Figure 2: Radiographic changes in patient two
Figure 1: Radiographic changes in patient one
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on the right lower lung zone with coarse crepitations on 
the left hemithorax, and blood pressure of 90/60 mmHg 
and oxygen saturation of 89% in room air which 
improved to 96% with administration of oxygen at 4 L/
min through nasal prongs (Table 1). Full blood count 
showed leukocytosis with lymphopenia, anemia, 
and thrombocytopenia (Table 2), sputum GeneXpert 
showed MTB detected high, HIV screening was 
negative, and liver function tests, electrolytes urea, and 
creatinine were within the normal limit (Table 2). Chest 
X-ray showed an extensive homogenous opacity with 
some coalescing in both lung fields, barely sparing the 
left apical and lower lung zone as well as the lower 
aspect of the right upper lung zone. There was an air 
bronchogram seen within these  opacities (Figure 2). 
He received antiviral (lopinavir/ritonavir), azithromycin, 
Vitamin C, zinc Sulfate, quadruple anti-TB agent and tabs 
pyridoxine, IV hydrocortisone, and thromboprophylaxis 
with clexane as well as oxygen therapy. On the 15th day, 
he developed hypotension (80/50 mmHg) with severe 
hypoxemia (oxygen saturation of 78%) despite oxygen 
through facemask with reservoir bag at 8–10 L/min and 
succumbed to the disease on the 6th day of admission.
Discussion
The two cases in this report had both 
COVID-19 and TB diagnosed about the same time, with 
the screening for TB based on the chest radiographic 
findings and symptoms suggestive of TB. This finding in 
our report (which the two patients never had treatment 
for pulmonary tuberculosis) is in contrast to observation 
from the case series in China where the patients had 
previous treatment for pulmonary tuberculosis. The 
detection of the TB for the first time while on admission 
for COVID-19 is not unexpected due to under-diagnosis 
and underreporting in most developing countries. 
Probably, they were cases of active TB moving within 
the community with the superimposing of COVID-19 
that precipitated acute illness prompting the admission. 
Whereas the patients had typical chronic symptoms 
(cough, fever, and weight loss) of TB, they both had 
symptoms of acute respiratory illness before admission. 
They were also in close contact with confirmed infection 
of COVID-19. This finding is keeping the case report of 
COVID-19 and TB from China [8]. Hence, a cautionary 
reminder to clinicians that mycobacterium infection 
status should be considered when treating COVID-19 
patients (especially in the presence of chronic cough) 
in TB endemic countries.
The main laboratory findings were lymphopenia 
and anemia for both patients. Besides, patient two had 
leukocytosis (who also had severe symptoms), and this 
is in keeping with the study that examined the laboratory 
abnormalities in patients with COVID-19 infection [11]. 
Whereas both patients had chest radiographic 
changes, they were more extensive in patient two, and 
he manifested severe symptoms. This observation 
probably reflected the impact of both COVID-19 and 
PTB, with more severe damage likely to have a poor 
outcome. Hence, the poor outcome observed in the 
patient-two.
Both patients had antiviral, zinc, azithromycin, 
and anti-TB agent and other treatments in addition to 
this oxygen therapy and glucocorticoid in the patient 
with severe disease. The WHO recommends that 
patient with TB follows all recommended precautions 
against COVID-19 and continues taking TB treatment 
throughout the pandemic [12].
Conclusion
This case reports showed that COVID-19 
superimposed on TB may not be uncommon in our 
environment and may have a poor outcome. Hence, 
there is a need for a high index of suspicion for TB 
infection in endemic areas during the COVID-19 
pandemic. Besides, we recommend screening for TB 
in patients with chronic cough with superimposed acute 
respiratory symptoms suggestive of COVID-19.
Acknowledgments
We thank the staff of the COVID-19 treatment 
center for their support in the care of the patients.
References
1. World Health Organization. Coronavirus Disease (COVID-19): 
Situation Report-164. Geneva: World Health Organization; 
2020.
2. World Health Organization. WHO Director-general’s Opening 
Remarks at the Media Briefing on COVID-19 2020. WHO 
Director General’s Speeches; 2020. Available from: https://www.
who.int/dg/speeches/detail/who-director-general-s-opening-
remarks-at-the-media-briefing-on-covid-19---11-march-2020. 
[Last accessed on 2020 Apr 05]. https://doi.org/10.1093/
ww/9780199540884.013.u23682
3. Nigeria Centre for Disease Control. Covid-19 Situation 
Report: Situation Report 129; 2020 Available from: https://
www.ncdc.gov.ng/themes/common/files/sitreps/6921d73 
6ae691c533067fe03b2c5e4db.pdf. [Last accessed on 2020 
July 03].
4. United States Agency for International Development. 
Tuberculosis Legal Environment Assessment (Nigeria): Final 
Report. United States: United States Agency for International 
 Tekobo et al. Tuberculosis in COVID-19 Patients
Open Access Maced J Med Sci. 2020 Oct 19; 8(T1):272-275. 275
Development; 2018.
5. Gupta A, Singla R, Caminero JA, Singla N, Mrigpuri P, Mohan A. 
Impact of COVID-19 on tuberculosis services in India. Int J Tuberc 
Lung Dis. 2020;24(6):637-9. https://doi.org/10.5588/ijtld.20.0212
 PMid:32553014
6. Nigerian Thoracic Society. COVID-19 Handbook (Consensus 
Statement on Management of COVID-19). 1st ed. United States: 
Nigerian Thoracic Society; 2020.
7. Boffa J, Mhlaba T, Sulis G, Moyo S, Sifumba Z, Pai M, et al. 
COVID-19 and tuberculosis in South Africa: A dangerous 
combination. South African Med J. 2020;110(5):341. https://doi.
org/10.7196/samj.2020.v110i5.14747
8. He G, Wu J, Shi J, Dai J, Gamber M, Jiang X, et al. COVID-19 in 
tuberculosis patients: A report of three cases. J Med Virol. 2020; 
92(10):2-6. https://doi.org/10.1002/jmv.25943. 
 PMid:32343410
9. Dara M, Sotgiu G, Reichler MR, Chiang C, Chee CB, Migliori GB. 
New diseases and old threats: Lessons from tuberculosis for the 
COVID-19 response. Int J Tuberc Lung Dis. 2020;24(5):544-5. 
https://doi.org/10.5588/ijtld.20.0151
 PMid:32398212
10. Tadolini M, Codecasa LR, García-García JM, Blanc FX, 
Borisov S, Alffenaar JW, et al. Active tuberculosis, 
sequelae and COVID-19 co-infection: First cohort of 49 
cases. Eur Respir J. 2020;56(1):2001398. https://doi.
org/10.1183/13993003.02328-2020
 PMid:32457198
11. Lippi G, Plebani M. Laboratory abnormalities in patients with 
COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4. 
 PMid:32119647
12. World Health Organization. World Health Organization (WHO) 
Information Note Tuberculosis and COVID-19 COVID-19 : 
Considerations for Tuberculosis (TB) Care. Geneva: World 
Health Organization; 2020. p. 1-11.
